X

Drug Profile

Trimegestone

Alternative Names: Ondeva; RU 27987; TMG

Latest Information Update: 25 Sep 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ProStrakan; sanofi-aventis
Class Hormonal replacements; Norpregnadienes; Osteoporosis therapies
Mechanism of Action Progesterone receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

18 Apr 2016 ProStrakan is now called Kyowa Kirin International
16 Oct 2009 Wyeth has been acquired by Pfizer
19 Sep 2007 Duramed Pharmaceuticals terminates its licence for trimegestone patch in the USA and Canada

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com